Point mutations in isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) genes identified in diffuse gliomas with different degrees of malignancy have become the main factor for molecular-based classification of gliomas. The gene discussed is IDH2; the disease is central nervous system cancer.